CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients

OBJECTIVE—: CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early recurrent cardiovascular events after acute myocardial infarction. Cholesterol efflux capacity (CEC) is a marker of high-density lipoprotein (HDL) function that is strongly...

Descripción completa

Detalles Bibliográficos
Autores principales: Gille, Andreas, D’Andrea, Denise, Tortorici, Michael A., Hartel, Gunter, Wright, Samuel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical and Population Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895137/
https://www.ncbi.nlm.nih.gov/pubmed/29437574
http://dx.doi.org/10.1161/ATVBAHA.118.310538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895137/
https://www.ncbi.nlm.nih.gov/pubmed/29437574
http://dx.doi.org/10.1161/ATVBAHA.118.310538

Ejemplares similares